Acute Coronary Syndrome

A point-of-care troponin assay that yields results within about 15 minutes was equally effective at ruling out acute myocardial infarction (AMI) as a high-sensitivity troponin I test performed in a laboratory setting, researchers reported in JAMA Cardiology.

For patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease, complete revascularization is associated with greater in-hospital mortality but better long-term survival, according to an observational study published Oct. 15 in the Journal of the American College of Cardiology.

Cystatin C (Cys-C), an alternative to renal markers like creatinine and glomerular filtration rate, can effectively predict a patient’s risk for adverse CVD events after an acute coronary syndrome (ACS), researchers reported Oct. 12 in the Journal of the American Heart Association.

The FDA has approved rivaroxaban to reduce the risk of major cardiovascular events including stroke, myocardial infarction and cardiovascular death for people with chronic peripheral or coronary artery disease (PAD/CAD).

A study presented at TCT 2018 questioned the benefits of “drip-and-ship” for elderly patients with ST-segment elevation myocardial infarction (STEMI), finding patients in their 80s or older who were transferred with fibrinolytic therapy for PCI had an eight-fold risk of hemorrhagic stroke but no survival advantage.

Fewer than one-third of Chinese patients with acute coronary syndromes (ACS) receive guidance to participate in cardiac rehabilitation, according to research presented Oct. 11 at the Great Wall International Congress of Cardiology.

People with unrecognized myocardial infarction carry a lower short-term risk of death but an equal 10-year risk of mortality compared to those with clinically diagnosed heart attacks, according to an analysis of the ICELAND MI study published in JAMA Cardiology.

For the first time, the World Health Organization (WHO) has included ambient noise from leisure-time activities in its guidelines on how cumulative exposure to high volumes can lead to health problems, including stress, hypertension and heart disease.

A genomic risk prediction tool developed by researchers in Australia and the U.K. has achieved greater risk discrimination than its predecessors while identifying patients at the highest and lowest likelihood of developing coronary artery disease (CAD), according to a study published ahead of print in the Journal of the American College of Cardiology.

A machine learning tool developed by researchers at Michigan State University can accurately predict an individual’s height within an inch and may offer more precise CVD and cancer risk assessment in the future, according to a report featured this month in Genetics.

Fractional flow reserve (FFR) can be closely approximated using conventional coronary angiography and propriety software, according to the FAST-FFR study published online in Circulation. The findings offer a potential route for more patients with suspected coronary artery disease to receive functional assessment of lesions without the need for a guidewire or hyperemic agents.

The Hospital Readmissions Reduction Program (HRRP) has successfully slashed readmissions for heart failure, acute MI (AMI) and pneumonia without causing mortality increases, according to an analysis of Medicare data published in JAMA Network Open. But the author of an accompanying editorial isn’t convinced the results are so positive.